NTHI

DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad

DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics. The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous system. That is

DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies. Maxim Group and Alliance Global Partners initiated coverage on NeOnc with a favorable ratings and targets, highlighting what the firms see as significant benefit potential relative to the company's current market position. BTIG Research also recently launched coverage with a advantageous rating and target, reflecting

Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp

Maxim Group initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00

SCHEDULE 13G - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Subject)

10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. At the center of this narrative sits a lesser-known but increasingly watched name: NeOnc Technologies (NASDAQ:NTHI), a company whose leadership is making a bold, highly vi

DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments. While insider buying is never a guarantee of upside, it frequently reflects conviction rooted in operational visibility, upcoming catalysts, or perceived undervaluation. Here's a closer look at five companies where insider activity is turning heads, and potentially signaling deeper narratives unfolding beneath the surface. NeOnc Technolo

CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones. Over the past year, Mr. Heshmatpour has invested nearly $1 million of personal capital into NeOnc shares. In r

10-K/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

BTIG Research initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $15.00

4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

Insider buying indicates management's conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout - expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study - within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. ("NTHI" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Chairman and CEO Amir Heshmatpour has purchased approximately $300,000 worth of NTHI stock in the last week, demonstrating managem